Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 05/01/2012 - 05/01/2015

This course is closed. Please look for other available products in CPNP University.

Session Summary

As evidenced by the ever-increasing research and continued public interest, drug development in autism is a crucial piece in the future of psychopharmacology.  However, due in part to the variability of symptoms in autism, researchers face many roadblocks in finding appropriate pharmacological treatment.

Dr. Craig Erickson, Chief of the Christian Sarkine Austism Treatment Center at Riley Hospital for Children in Indianapolis, will break down the most current neuropathology research in autism and help us to understand some of the difficulties in finding appropriate pharmacotherapy for social and communication deficits.  He will take a second look at some of the “failed” agents for autism and those needing more evidence.  Additionally, Dr. Erickson will take a look at the potential role of the glutamate pathway in treatment of autism, reviewing some of the most current research available.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • Receive a passing grade (60%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This session was presented live at the 2012 CPNP Annual Meeting. A PDF file of the slides and audio of the speaker’s presentation is provided. ACPE transcripts can be retrieved by participants online at cpnp.org and the credit will be automatically submitted to your account at CPE Monitor shortly after the evaluation is completed.

Faculty Information and Disclosures

Learning Objectives

  1. Discuss briefly the current thought on neuropathology responsible for social and communication impairments in Autism.
  2. Understand the challenges in discovery of pharmacotherapy for social and communication deficits.
  3. Outline the pharmacologic agents that have been found ineffective and those needing more studies including naltrexone, fenfluramine, secretin, oxytocin, cholinergic drugs and SSRIs.
  4. Discuss the potential use of glutametergic agents to target social and communication impairments in autism and current clinical trials assessing their safety and efficacy.

Continuing Education Credit and Disclosures

Activity Dates: 05/01/2012 - 05/01/2015
ACPE Contact Hours: 1.0
ACPE Number: 0284-9999-12-013-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPE Credit

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


CME Credit

Sponsored by the University of Arizona College of Medicine at the Arizona Health Sciences Center.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint sponsorship of The University of Arizona College of Medicine at the Arizona Health Sciences Center and the College of Psychiatric and Neurologic Pharmacists. ACCME credit is no longer available for this course.

Nursing Credit

ACPE and ACCME approved contact hours are accepted for ANCC Certification Renewal (as quoted on the ANCC website):  “Other health disciplines' continuing education hours may be used if the content is applicable to your area of certification. ACPE and ACCME are specifically listed as approved credit types.

Grant Support

Annual Meeting Grant Supporter